logo
  Join        Login             Stock Quote

Illumina (ILMN) Estimates Cut By Oppenheimer After Q1, 'Perform' Reiterated

 April 24, 2012 02:36 PM
 


(By Balaseshan S) Oppenheimer & Co. analyst David Ferreiro reiterated his "Perform" rating on shares of Illumina Inc. (NASDAQ:ILMN) given the heightened competition in the NGS marketplace and the expectation for continued weakness in the microarray market.

The brokerage lowered its 2012 EPS estimate to $1.43 from $1.45, while raising its 2013 estimate to $1.61 from $1.59. The firm reduced its 2012 revenue estimate to $1.12 billion from $1.15 billion and its 2013 estimate to $1.19 billion from $1.20 billion.

ILMN revenues of $273 million were down 3% year-over-year and despite distraction from Roche's bid, ILMN delivered strong sequential growth in consumables ($173 million, up 20% sequentially). Consumable results were led by a trifecta of drivers: a rebound in HiSeq consumables, strong MiSeq placements, and exome array's sales.

[Related -Laboratory Corp. of America Holdings (LH): Why Obamacare Could Propel This Stock To A 70% Gain]

ILMN remains on track to ship the HiSeq and MiSeq upgrades in the second half of 2012. Although Q1 results were better than expected, Ferreiro views the lack of a guidance increase as troubling, and wonder if ILMN aggressively pulled revenue forward in response to the Roche bid.

Revenues of $273 million saw consumable pull-through of 299,000/year, a number ILMN believes will increase due to the scheduled Q2 price increase. In addition, higher U.S./Asia-Pac utilization rates, overall sequencing consumable orders growth, and increased exome array utilization bolstered revenues. Adjusted EPS of $0.36 are above the analyst's/Street's $0.32 estimates.

[Related -Futures Up After Apple, Inc. (AAPL) Earnings; Maidenform Brands, Inc. (MFB) Surges On Buyout News]

ILMN notes that orders placed in advance of its Q2-2012 price increase have increased backlog visibility and allowed for manufacturing efficiency. However, considering the recent V3 chemistry extra capacity issue, Ferreiro worries demand might wane following the Q2-2012 price increase.

MiSeq pricing held up, and ILMN claimed average selling prices were slightly higher than list. Greater than half of MiSeq sales were to diagnostic customers, in contrast to HiSeq, which remains primarily an academic tool. Ferreiro estimates ILMN placed 200 MiSeq systems in Q1-2012. A 510K submission is expected by year-end 2012.

The global funding environment is more stable than in 2011 with the U.S. exhibiting normalized buying patterns, the EU growing and Asia delivering the strongest growth (+20% sequentially). Additionally, ILMN believes sequestration is unlikely. While it is difficult to predict NIH budgeting, Ferreiro remains confident that bipartisan support will persist.

ILMN reaffirmed 2012 guidance for revenue of $1.1 billion to $1.175 billion and EPS of $1.40 to $1.50. Given better than expected Q1 revenue/EPS, Ferreiro is cautious on management's unchanged outlook.

Illumina is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics.

ILMN is trading down 1.50% at $43.24 on Tuesday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageRussell 2000 Showing Relative Weakness at the New Highs

A quick “Quad Index” Grid shows us that the small-cap Russell 2000 is showing relative strength to the read on...

article imageThe Poster Boy For Liberal Economics Discovers The Tax Factor

Paul Krugman seems to be having a supply-side-economics moment… sort of. Raising taxes, the NY Times read on...

article imageMacroprudential Policy And Distribution Of Risk

There is very little doubt that housing prices and leverage played a strong role in the global financial read on...

article imageIs the World Turning Japanese?

Many really think so, but reality suggests read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.